Floatz logo

Pexidartinib

Stage I Prostate Adenocarcinoma

Barbara Ann Karmanos Cancer InstituteSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

97 Active assets in the Stage I Prostate Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Docetaxel
Instituto do Cancer do Estado de São Paulo
Phase 3BBB
NILUTAMIDE
SWOG Cancer Research Network
Phase 3BB
PREDNISONE TABLETS
Mayo Clinic
Phase 3BB
Degarelix
Canadian Cancer Trials Group
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB

View all 50 →

Same molecule, other indications

Pexidartinib is also rated in:

glioblastomaDormant
B
Indicative ·
61 / 100
View asset →
melanomaDormant
CCC
Indicative ·
55 / 100
View asset →
angiosarcomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →